Moleculin Biotech Achieves Threefold CR Advantage in MIRACLE Trial Ahead of 2027 NDA Path

With a pivotal efficacy readout scheduled between December 2026 and February 2027, Moleculin Biotech's MIRACLE trial is entering the window where NDA submission planning and manufacturing scale-up decisions can no longer be deferred. Interim unblinded data from the first 45 patients in Part A show complete remission (CR) rates of 43% and 36% across the two Annamycin dose cohorts, 190 mg/m² and 230 mg/m² each combined with cytarabine, against a 12% CR rate in the cytarabine control arm. Composite complete remission (CRc) reached 50% and 57%, respectively, versus 29% for control.

The enrolled population skews toward a historically difficult-to-treat cohort: 75.6% of patients were over 60, and prior therapies included 7+3 regimens (55.6%) and venetoclax-based first-line treatment (31.1%). That context matters for regulatory affairs leads assessing the clinical dataset's generalisability and for QA teams anticipating the patient population's complexity in any eventual label negotiation.

Enrollment in Part A is tracking to the 90-patient milestone in September 2026. The full unblinded readout from that cohort will determine optimal dose selection and trigger Part B initiation, expected in the first half of 2027. For manufacturing and supply-chain functions, the Part B start signals the point at which commercial-scale process validation planning should be synchronised with clinical timelines, particularly given anthracycline manufacturing's established GMP complexity around potent compound handling and sterility assurance.

A consistent absence of cardiotoxicity, confirmed through cumulative anthracycline exposure levels exceeding conventional limits and presented at the 2026 ASCO Annual Meeting, differentiates Annamycin from standard anthracyclines. That safety signal has regulatory implications: a differentiated cardiac profile may support a broader label and reduce post-marketing commitment burden, though the agency's position will depend on the full dataset submitted under 21 CFR Part 312 end-of-Phase 2 meeting outcomes.

Moleculin reported cash on hand plus $9.3 million in post-quarter financing proceeds, with runway projected into the first quarter of 2027, aligning closely with the efficacy readout window but leaving limited buffer for pre-NDA manufacturing activities if the data support accelerated submission.

The December 2026 to February 2027 efficacy readout will be the measurable checkpoint against which Moleculin's regulatory and manufacturing readiness will be tested.

Source: Moleculin Biotech, Inc. via GlobeNewswire, August 14, 2026.